Kodiak Sciences to Present at 2026 Jefferies Global Healthcare Conference
Rhea-AI Summary
Kodiak Sciences (Nasdaq: KOD) announced that CEO Victor Perlroth, M.D., will present at the 2026 Jefferies Global Healthcare Conference in New York on Thursday, June 4, 2026, at 11:40 a.m. ET (8:40 a.m. PT).
A live webcast and limited-time replay will be accessible via the company’s investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction – KOD
In the May 29 session, KOD gained 1.63%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 07 | Earnings & pipeline | Positive | -6.1% | Q1 2026 financials with positive GLOW2 and pipeline progress but shares fell. |
| May 01 | Conference clinical data | Positive | +1.1% | Upcoming scientific conference talks highlighting KSI-101 clinical and preclinical advances. |
| Mar 31 | Earnings & strategy | Positive | +12.3% | Q4 and FY2025 results plus strong GLOW2 topline and capital raise details. |
| Mar 26 | Phase 3 topline | Positive | +74.8% | Positive GLOW2 Phase 3 diabetic retinopathy results positioning Zenkuda as BLA-ready. |
| Feb 04 | Phase 1b results | Positive | -6.9% | Announcement of final APEX Phase 1b data for KSI-101 ahead of conference presentation. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent clinically positive or earnings-linked news often led to upside, but there are instances where positive updates were followed by declines.
Over the last six months, KOD has reported multiple late-stage retina program milestones and financing-related updates. Positive Phase 3 GLOW2 data for Zenkuda on Mar 26 drove a 74.77% move, and the Q4/FY25 update on Mar 31 saw shares rise 12.3%. Subsequent Q1 2026 results and highlights on May 7 produced a -6.11% reaction despite clinical progress and cash runway commentary. Earlier APEX Phase 1b data communication on Feb 4 also saw a -6.87% move, underscoring mixed reactions to otherwise constructive clinical news.
AI-generated analysis. How Rhea-AI works. Not financial advice.
A live webcast of the presentation will be available on the "Events and Presentations" section of Kodiak's website at http://ir.kodiak.com/ and will remain available for replay for a limited time following the event.
About Kodiak Sciences Inc.
Kodiak Sciences (Nasdaq: KOD) is a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics. We are focused on bringing new science to the design and manufacture of next-generation retinal medicines to prevent and treat the leading causes of blindness globally. We are developing a portfolio of three late-stage clinical programs: Zenkuda™ (tarcocimab tedromer), KSI-501 and KSI-101.
For more information, please visit www.kodiak.com.
Kodiak®, Kodiak Sciences®, ABC®, ABC Platform®, ABCD™ and the Kodiak logo are registered trademarks or trademarks of Kodiak Sciences Inc. in various global jurisdictions.
View original content:https://www.prnewswire.com/news-releases/kodiak-sciences-to-present-at-2026-jefferies-global-healthcare-conference-302785078.html
SOURCE Kodiak Sciences Inc.